Solid Biosciences Inc. SLDB 深 滬

美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级

今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元

05-19 10:55

Wedbush Reiterates Outperform on Solid Biosciences, Maintains $16 Price Target

Wedbush analyst Laura Chico reiterates Solid Biosciences (NASDAQ:SLDB) with a Outperform and maintains $16 price target.

05-18 20:34

美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"

今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元

05-14 14:32

Solid Biosciences Q1 EPS $(0.52) Misses $(0.44) Estimate

Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.44) by 18.18 percent. This is a 11.86 percent increase over losses of $(0.59) per share

05-13 04:41

Solid Biosciences Doses First Participant In Phase 3 IMPACT DUCHENNE Clinical Trial For SGT-003 In Duchenne Muscular Dystrophy

- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid's integrated, multi-trial development program designed to support registration and global regulatory

05-07 20:06

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05-01 20:05

Solid Biosciences Says European Commission Grants Orphan Drug Designation To SGT-003 For Treatment Of Duchenne Muscular Dystrophy

- Orphan drug designation from the European Commission underscores Solid's commitment to advance SGT-003 through a global development effort for individuals living with Duchenne muscular dystrophy - CHARLESTOWN,

04-28 20:02

Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

Solid Biosciences' SGT-003 receives orphan drug designation from the European Commission for treating Duchenne muscular dystrophy, recognizing its potential to address unmet needs. The designation supports global development efforts, complementing previous U.K. ILAP and U.S. Fast Track designations. SGT-003 is being tested in Phase 1/2 and 3 trials, targeting muscle and heart function improvements.

04-28 12:00

Solid Biosciences Adjusts Board Classes in Governance Move

An announcement from Solid Biosciences ( ($SLDB) ) is now available. Solid Bios...

04-11 04:33

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences Inc. announced its participation in two investor conferences: the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026, and the Piper Sandler Spring Biopharma Symposium on April 16, 2026. The company focuses on developing precision genetic medicines for rare neuromuscular and cardiac diseases. A live webcast of the Needham event will be available on the company’s website.

04-07 12:00